Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ascendis Pharma (ASND – Research Report) and Abeona Therapeutics (ABEO – Research Report).
Ascendis Pharma (ASND)
SVB Securities analyst Joseph Schwartz maintained a Buy rating on Ascendis Pharma today and set a price target of $148.00. The company’s shares closed last Monday at $109.82.
According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $153.27, representing a 34.1% upside. In a report issued on October 31, Berenberg Bank also maintained a Buy rating on the stock with a $166.00 price target.
See today’s best-performing stocks on TipRanks >>
Abeona Therapeutics (ABEO)
In a report released today, Mani Foroohar from SVB Securities maintained a Hold rating on Abeona Therapeutics, with a price target of $6.00. The company’s shares closed last Monday at $4.20, close to its 52-week low of $2.70.
According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Abeona Therapeutics with a $23.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ASND:
- Monday.com (MNDY) Receives a Buy from Piper Sandler
- Analysts Offer Insights on Financial Companies: Bank Of Montreal (BMO) and Choice Properties Real Estate Investment (OtherPPRQF)
- ACV Returns to Used Car Week 2022 as Active Sponsor and Exhibitor
- National Bank Sticks to Their Buy Rating for CES Energy Solutions (CESDF)
- Kelt Exploration (KELTF) Gets a Buy from CIBC
